Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 58, 3620-3626, August 15, 1998]
© 1998 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Torres, K.
Right arrow Articles by Horwitz, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torres, K.
Right arrow Articles by Horwitz, S. B.

Mechanisms of Taxol-induced Cell Death Are Concentration Dependent1

Keila Torres and Susan Band Horwitz2

Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461

Although the ability of Taxol to stabilize cellular microtubules is well accepted, the mechanisms by which Taxol induces growth arrest and cell death remain unclear. Recent evidence indicates that Taxol alters specific intracellular signal transduction events, such as the activation of Raf-1 kinase, that may be essential for drug-induced apoptosis. To determine whether Raf-1 kinase activation occurs at different concentrations of Taxol and in response to disruption of the normal microtubule cytoskeleton, A549 cells were treated with different concentrations of Taxol after which Raf-1 activation and the microtubule cytoskeleton were analyzed. Raf-1 activation was observed at Taxol concentrations of 9 nM and greater. However, disruption of the normal microtubule cytoskeleton was seen at lower Taxol concentrations (1–7 nM), indicating that this process begins in the absence of Raf-1 activation. Raf-1 activation correlated with the induction of a G2-M block. Depletion of Raf-1 resulted in the accumulation of cells in the G2-M phase of the cell cycle, suggesting that Raf-1 may play an important role in the passage through mitosis. Supporting this idea, Raf-1 was activated in mitotic cells. Low concentrations of Taxol induced cell death in the absence of Raf-1 activation, indicating that Taxol-induced cell death is not dependent on Raf-1 activation. At concentrations of drug lower than the critical concentration required for Raf-1 activation, p53 and p21WAF-1 were induced independently of Raf-1. These studies suggest that Taxol-mediated cell death may result from two different mechanisms. At low Taxol concentrations (<9 nM), cell death may occur after an aberrant mitosis by a Raf-1 independent pathway, whereas at higher Taxol concentrations (≥9 nM) cell death may be the result of a terminal mitotic arrest occurring by a Raf-1-dependent pathway.

1 Supported by NCI Grant CA39821, NCI Cancer Core Grant CA13330, and by the National Cancer Institute Training Program in Viral Oncology and Tumor Biology Grant 2T32 CA09060 (to K. T.).

2 To whom requests for reprints should be addressed, at Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.

Received 2/ 6/98. Accepted 6/11/98.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. F. Beyer, N. Zhang, R. Hernandez, D. Vitale, J. Lucas, T. Nguyen, C. Discafani, S. Ayral-Kaloustian, and J. J. Gibbons
TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity
Cancer Res., April 1, 2008; 68(7): 2292 - 2300.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
Ann. Onc., February 1, 2008; 19(2): 223 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. P. Gan, E. Pasquier, and M. Kavallaris
Class III {beta}-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer
Cancer Res., October 1, 2007; 67(19): 9356 - 9363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Choe, Z. Chen, C. M. Klass, X. Zhang, and D. M. Shin
Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., May 15, 2007; 13(10): 3015 - 3023.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. Michalakis, S. D. Georgatos, E. de Bree, H. Polioudaki, J. Romanos, V. Georgoulias, D. D. Tsiftsis, and P. A. Theodoropoulos
Short-Term Exposure of Cancer Cells to Micromolar Doses of Paclitaxel, with or without Hyperthermia, Induces Long-Term Inhibition of Cell Proliferation and Cell Death In Vitro
Ann. Surg. Oncol., March 1, 2007; 14(3): 1220 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
R. van Amerongen and A. Berns
TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?
Genes & Dev., August 1, 2006; 20(15): 1975 - 1981.
[Full Text] [PDF]

Home page
 J. Cell Biol.Home page
M. Blank, Y. Lerenthal, L. Mittelman, and Y. Shiloh
Condensin I recruitment and uneven chromatin condensation precede mitotic cell death in response to DNA damage
J. Cell Biol., July 17, 2006; 174(2): 195 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Russo, P. G. Magro, Z. Hu, W.-W. Li, R. Peters, J. Mandola, D. Banerjee, and J. R. Bertino
E2F-1 Overexpression in U2OS Cells Increases Cyclin B1 Levels and cdc2 Kinase Activity and Sensitizes Cells to Antimitotic Agents.
Cancer Res., July 15, 2006; 66(14): 7253 - 7260.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. L. Morse, H. Gray, C. M. Payne, and R. J. Gillies
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1495 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. N. Demidenko, D. Halicka, J. Kunicki, J. A. McCubrey, Z. Darzynkiewicz, and M. V. Blagosklonny
Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel
Cancer Res., May 15, 2005; 65(10): 4401 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
Aspen Cancer Conference Fellows
Toxicol Pathol, October 1, 2004; 32(6): 749 - 761.
[PDF]

Home page
 Clin. Cancer Res.Home page
M. Suggitt, D. J. Swaine, G. R. Pettit, and M. C. Bibby
Characterization of the Hollow Fiber Assay for the Determination of Microtubule Disruption In vivo
Clin. Cancer Res., October 1, 2004; 10(19): 6677 - 6685.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. M. Pushkarev, D. V. Starenki, V. A. Saenko, H. Namba, J. Kurebayashi, M. D. Tronko, and S. Yamashita
Molecular Mechanisms of the Effects of Low Concentrations of Taxol in Anaplastic Thyroid Cancer Cells
Endocrinology, July 1, 2004; 145(7): 3143 - 3152.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Blank, M. Mandel, Y. Keisari, D. Meruelo, and G. Lavie
Enhanced Ubiquitinylation of Heat Shock Protein 90 as a Potential Mechanism for Mitotic Cell Death in Cancer Cells Induced with Hypericin
Cancer Res., December 1, 2003; 63(23): 8241 - 8247.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-G. Chen, C.-P. H. Yang, M. Cammer, and S. Band Horwitz
Gene Expression and Mitotic Exit Induced by Microtubule-Stabilizing Drugs
Cancer Res., November 15, 2003; 63(22): 7891 - 7899.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. P. MacKeigan, C. M. Clements, J. D. Lich, R. M. Pope, Y. Hod, and J. P-Y. Ting
Proteomic Profiling Drug-Induced Apoptosis in Non-Small Cell Lung Carcinoma: Identification of RS/DJ-1 and RhoGDI{alpha}
Cancer Res., October 15, 2003; 63(20): 6928 - 6934.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Takimoto and E. K. Rowinsky
Dose-Intense Paclitaxel: Deja Vu All Over Again?
J. Clin. Oncol., August 1, 2003; 21(15): 2810 - 2814.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. C. Holsinger, D. D. Doan, S. A. Jasser, E. A. Swan, J. S. Greenberg, B. A. Schiff, B. N. Bekele, M. N. Younes, C. D. Bucana, I. J. Fidler, et al.
Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer
Clin. Cancer Res., August 1, 2003; 9(8): 3183 - 3189.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Kelling, K. Sullivan, L. Wilson, and M. A. Jordan
Suppression of Centromere Dynamics by Taxol(R) in Living Osteosarcoma Cells
Cancer Res., June 1, 2003; 63(11): 2794 - 2801.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Asakuma, M. Sumitomo, T. Asano, T. Asano, and M. Hayakawa
Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel
Cancer Res., March 15, 2003; 63(6): 1365 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Giannakakou, M. Nakano, K. C. Nicolaou, A. O'Brate, J. Yu, M. V. Blagosklonny, U. F. Greber, and T. Fojo
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics
PNAS, August 6, 2002; 99(16): 10855 - 10860.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. E. Broker, C. Huisman, C. G. Ferreira, J. A. Rodriguez, F. A. E. Kruyt, and G. Giaccone
Late Activation of Apoptotic Pathways Plays a Negligible Role in Mediating the Cytotoxic Effects of Discodermolide and Epothilone B in Non-Small Cell Lung Cancer Cells
Cancer Res., July 15, 2002; 62(14): 4081 - 4088.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. McDaid, S. Mani, H.-J. Shen, F. Muggia, D. Sonnichsen, and S. B. Horwitz
Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, during a Phase I Clinical Study
Clin. Cancer Res., July 1, 2002; 8(7): 2035 - 2043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. MacKeigan, D. J. Taxman, D. Hunter, H. S. Earp III, L. M. Graves, and J. P-Y. Ting
Inactivation of the Antiapoptotic Phosphatidylinositol 3-Kinase-Akt Pathway by the Combined Treatment of Taxol and Mitogen-activated Protein Kinase Kinase Inhibition
Clin. Cancer Res., July 1, 2002; 8(7): 2091 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-G. Chen and S. B. Horwitz
Differential Mitotic Responses to Microtubule-stabilizing and -destabilizing Drugs
Cancer Res., April 1, 2002; 62(7): 1935 - 1938.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Auzenne, N. J. Donato, C. Li, E. Leroux, R. E. Price, D. Farquhar, and J. Klostergaard
Superior Therapeutic Profile of Poly-L-Glutamic Acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma
Clin. Cancer Res., February 1, 2002; 8(2): 573 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. M. McDaid and S. B. Horwitz
Selective Potentiation of Paclitaxel (Taxol)-Induced Cell Death by Mitogen-Activated Protein Kinase Kinase Inhibition in Human Cancer Cell Lines
Mol. Pharmacol., August 1, 2001; 60(2): 290 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Sausville
Combining Cytotoxics and 17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters : Commentary re: P. Munster et al., Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB- and Schedule-dependent Manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Clin. Cancer Res., August 1, 2001; 7(8): 2155 - 2158.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, J. W. Slaton, P. Perrotte, D. W. Davis, C. J. Bruns, D. J. Hicklin, D. J. McConkey, P. Sweeney, R. Radinsky, and C. P. N. Dinney
Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma
Clin. Cancer Res., December 1, 2000; 6(12): 4874 - 4884.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Y. Mitsuuchi, S. W. Johnson, M. Selvakumaran, S. J. Williams, T. C. Hamilton, and J. R. Testa
The Phosphatidylinositol 3-Kinase/AKT Signal Transduction Pathway Plays a Critical Role in the Expression of p21WAF1/CIP1/SDI1 Induced by Cisplatin and Paclitaxel
Cancer Res., October 1, 2000; 60(19): 5390 - 5394.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M. Roberge, B. Cinel, H. J. Anderson, L. Lim, X. Jiang, L. Xu, C. M. Bigg, M. T. Kelly, and R. J. Andersen
Cell-based Screen for Antimitotic Agents and Identification of Analogues of Rhizoxin, Eleutherobin, and Paclitaxel in Natural Extracts
Cancer Res., September 1, 2000; 60(18): 5052 - 5058.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C.-P. H. Yang and S. B. Horwitz
Taxol Mediates Serine Phosphorylation of the 66-kDa Shc Isoform
Cancer Res., September 1, 2000; 60(18): 5171 - 5178.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Y. Huang, K. R. Johnson, J. S. Norris, and W. Fan
Nuclear Factor-{{kappa}}B/I{{kappa}}B Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells
Cancer Res., August 1, 2000; 60(16): 4426 - 4432.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M. V. Blagosklonny, P. C. Bishop, R. Robey, T. Fojo, and S. E. Bates
Loss of Cell Cycle Control Allows Selective Microtubule-active Drug-induced Bcl-2 Phosphorylation and Cytotoxicity in Autonomous Cancer Cells
Cancer Res., July 1, 2000; 60(13): 3425 - 3428.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. Giannakakou and T. Fojo
Discodermolide: Just Another Microtubule-stabilizing Agent? No! A Lesson in Synergy
Clin. Cancer Res., May 1, 2000; 6(5): 1613 - 1615.
[Full Text]

Home page
 Clin. Cancer Res.Home page
L. A. Martello, H. M. McDaid, D. L. Regl, C.-P. H. Yang, D. Meng, T. R. R. Pettus, M. D. Kaufman, H. Arimoto, S. J. Danishefsky, A. B. Smith III, et al.
Taxol and Discodermolide Represent a Synergistic Drug Combination in Human Carcinoma Cell Lines
Clin. Cancer Res., May 1, 2000; 6(5): 1978 - 1987.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
E. Harper, W. Dang, R. G. Lapidus, and R. I. Garver Jr.
Enhanced Efficacy of a Novel Controlled Release Paclitaxel Formulation (PACLIMER Delivery System) for Local-Regional Therapy of Lung Cancer Tumor Nodules in Mice
Clin. Cancer Res., December 1, 1999; 5(12): 4242 - 4248.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Kurdoglu, N. Cheong, J. Guan, B. W. Corn, W. J. Curran Jr., and G. Iliakis
Apoptosis as a Predictor of Paclitaxel-induced Radiosensitization in Human Tumor Cell Lines
Clin. Cancer Res., September 1, 1999; 5(9): 2580 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B.-D. Chang, E. V. Broude, M. Dokmanovic, H. Zhu, A. Ruth, Y. Xuan, E. S. Kandel, E. Lausch, K. Christov, and I. B. Roninson
A Senescence-like Phenotype Distinguishes Tumor Cells That Undergo Terminal Proliferation Arrest after Exposure to Anticancer Agents
Cancer Res., August 1, 1999; 59(15): 3761 - 3767.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky
On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope
Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. D. Laird, D. K. Morrison, and D. Shalloway
Characterization of Raf-1 Activation in Mitosis
J. Biol. Chem., February 12, 1999; 274(7): 4430 - 4439.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. McDaid and P. G. Johnston
Synergistic Interaction between Paclitaxel and 8-Chloro-adenosine 3',5'-Monophosphate in Human Ovarian Carcinoma Cell Lines
Clin. Cancer Res., January 1, 1999; 5(1): 215 - 220.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. P. MacKeigan, T. S. Collins, and J. P.-Y. Ting
MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis
J. Biol. Chem., December 8, 2000; 275(50): 38953 - 38956.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Hayne, G. Tzivion, and Z. Luo
Raf-1/MEK/MAPK Pathway Is Necessary for the G2/M Transition Induced by Nocodazole
J. Biol. Chem., October 6, 2000; 275(41): 31876 - 31882.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Fan, M. Goodwin, T. Vu, C. Brantley-Finley, W. A. Gaarde, and T. C. Chambers
Vinblastine-induced Phosphorylation of Bcl-2 and Bcl-XL Is Mediated by JNK and Occurs in Parallel with Inactivation of the Raf-1/MEK/ERK Cascade
J. Biol. Chem., September 22, 2000; 275(39): 29980 - 29985.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.